Page 5 - Nasdaq Rlmd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq rlmd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Rlmd Today - Breaking & Trending Today

Zacks: Brokerages Expect Relmada Therapeutics, Inc. (NASDAQ:RLMD) Will Post Earnings of -$1.30 Per Share

Equities research analysts expect Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) to report earnings of ($1.30) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Relmada Therapeutics’ earnings, with estimates ranging from ($1.32) to ($1.27). Relmada Therapeutics posted earnings of ($1.56) per share during the same quarter last […] ....

United States , Paul Edward Kelly , Great Point Partners , Relmada Therapeutics Inc , Walleye Capital , Zacks Investment Research , Goldman Sachs Group , Weiss Multi Strategy Advisers , Relmada Therapeutics , Get Rating , Relmada Therapeutic , Investment Research , Director Paul Edward Kelly , Multi Strategy Advisers , Point Partners , California State Teachers Retirement System , State Teachers Retirement System , Nasdaq Rlmd ,

Brokerages Expect Relmada Therapeutics, Inc. (NASDAQ:RLMD) Will Announce Earnings of -$1.21 Per Share

Brokerages expect Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) to announce ($1.21) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Relmada Therapeutics’ earnings. The lowest EPS estimate is ($1.26) and the highest is ($1.12). Relmada Therapeutics reported earnings per share of ($1.34) in […] ....

Paul Edward Kelly , Securities Exchange Commission , Zacks Investment Research , Swiss National Bank , Deutsche Bank , Relmada Therapeutics Inc , Nisa Investment Advisors , Goldman Sachs Group , Byrne Asset Management , Relmada Therapeutics Company Profile Get Rating , Relmada Therapeutics , Get Rating , Zacks Investment , Relmada Therapeutic , Director Paul Edward Kelly , Exchange Commission , Investment Advisors , Asset Management , National Bank , Therapeutics Company Profile , Nasdaq Rlmd ,

Relmada Therapeutics (NASDAQ:RLMD) Stock Price Up 2.6%

Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating)’s stock price shot up 2.6% on Tuesday . The stock traded as high as $30.78 and last traded at $30.73. 916 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 339,304 shares. The stock had previously closed at $29.96. A number […] ....

Morgan Stanley , Geode Capital Management , Zacks Investment Research , Blackrock Inc , Relmada Therapeutics Company Profile , Relmada Therapeutics Inc , Parsons Capital Management Inc , Goldman Sachs Group , Relmada Therapeutics , Get Rating , Investment Research , Capital Management , Therapeutics Company Profile , New Chemical Entity , Nasdaq Rlmd ,

Relmada Therapeutics (RLMD) Scheduled to Post Quarterly Earnings on Wednesday

Relmada Therapeutics (NASDAQ:RLMD – Get Rating) will issue its quarterly earnings data after the market closes on Wednesday, March 23rd. Analysts expect the company to announce earnings of ($1.47) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link. Shares of NASDAQ RLMD […] ....

United States , Relmada Therapeutics Inc , Wells Fargo Company , Charles Schwab Investment Management Inc , Zacks Investment Research , Group Plc , Relmada Therapeutics Company Profile Get Rating , Relmada Therapeutics , Get Rating , Investment Research , General Group Plc , Schwab Investment Management , State Teachers Retirement System , Therapeutics Company Profile , New Chemical Entity , Nasdaq Rlmd ,